ADCs and armed antibodies at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

18 organizations at Festival of Biologics 2026 present work in adcs & armed antibodies: 11 drug developers and 7 suppliers and service providers. Between them they bring 19 presentations to the program. Most represented: Pierre Fabre (2 on the program), Memorises Bio (2 on the program), Mabqi (2 on the program). 12 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–16 of 18 organizations

Organization	Festival of Biologics 2026 Attendance
Pierre Fabre
pierre-fabre.com Large pharma French pharmaceutical and dermo-cosmetics group with oncology and dermatology medicines.	Chair Tue Oct 13 09:05 Chair's Opening Remarks Keynotes Keynote Tue Oct 13 11:30 Antibody-Based Products: Successes & Progresses in 2026 Antibody Keynotes Talk Wed Oct 14 11:30 Characterization and Developability of Next-Generation Biologics: ADCs, CAR T Cells, rAAVs, mRNA and VLPs CMC & Developability Chair Wed Oct 14 14:05 Chair's Remarks Armed antibodies
MB Memorises Bio
Biotech Therapeutic antibody discovery company spun out of Memo Therapeutics, keeping its DROPZYLLA discovery platform.	Talk Tue Oct 13 16:50 Adaptive trial designs to expedite clinical development Ways to design clinical trials that adapt as data arrive to speed up development, with regulatory lessons and real company examples. Talk Wed Oct 14 11:30 Discovery of novel tumor derived antibody/target pairs for ADC drug development How antibody libraries built from tumors reveal new cancer targets, with early proof that antibody–drug conjugates against them can work. Talk Wed Oct 14 14:10 Title TBA Antibodies for Immunotherapy
M Mabqi
Biotech Develops therapeutic antibodies and antibody-drug conjugates for cancer.	Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 12:10 Next-Generation Tumor-Specific Anti-CD30 ADC as a New Therapy in Hemato-Oncology Armed antibodies Talk Wed Oct 14 12:30 A Novel Pan-Cancer TRPV6-Targeted Therapy Driving Antitumor Activity Through Ion Channel Modulation Why an ion channel that helps tumors grow may be a drug target in many cancers, with lab and animal tests of a therapy.
LX LYO-X
Consulting & services Pharmacometrics consultancy offering PK/PD and quantitative systems pharmacology modelling for drug development.	Talk Tue Oct 13 13:30 First in Human Dose Selection for ADCs and TCEs Using PK/PD and QSP How computer models of drug behavior help pick safe yet active first human doses for antibody–drug conjugates and T cell engagers. Clinical developmentADCs & armed antibodies Chair Tue Oct 13 16:45 Chair's Remarks Antibodies for Immunotherapy
NB Nona Biosciences
Reagents & discovery tools Harbour BioMed's discovery company, offering Harbour Mice antibody platforms (H2L2, HCAb) and discovery services for antibodies, multispecifics, ADCs and CAR-T binders.	Booth Exhibiting at Booth 424 Keynote Wed Oct 14 09:30 Novel Next-generation Multispecifics, CAR-Ts & ADCs from H2L2 & HCAb Harbour Mice® How mice that make human antibodies, including heavy-chain-only ones, are used to build multi-target antibodies, CAR-T cells and antibody–drug conjugates for cancer. Bispecifics & multispecificsADCs & armed antibodies
WuXi XDC
wuxixdc.com CDMO & CRODiamond sponsor CRDMO for ADCs and other bioconjugates, providing end-to-end contract research, development and manufacturing, including antibody intermediates.	Booth Exhibiting (no floor booth listed) Keynote Tue Oct 13 11:55 Empowering the Next Wave of ADC and Bioconjugate Innovation with Cutting-Edge Technologies How attaching two different drug payloads to one antibody in precise numbers could make stronger antibody–drug conjugates that overcome tumor drug resistance.
Adherent Health
adherentbio.com Biotech Biotech start-up developing multispecific biologics against tumor-restricted antigens to overcome tumor resistance, using its Suprabody engine.	Talk Wed Oct 14 12:30 Title TBA Armed antibodies
AB Araris Biotech
	Talk Wed Oct 14 14:30 Novel Multi-Payload ADCs Assembled in One Step from Native Antibodies show High Efficacy and Tolerability in vivo Armed antibodies
Genentech South San Francisco, CA
	Chair Wed Oct 14 11:25 Chair's Remarks Armed antibodies
Innate Pharma Marseille, France
innate-pharma.com Biotech Develops antibody-based immunotherapies for cancer, including NK cell engagers and antibody-drug conjugates.	Talk Wed Oct 14 15:30 Preclinical characterization of IPH4502, a differentiated Nectin-4-targeted exatecan ADC Preclinical results for a new antibody–drug conjugate against Nectin-4 that beat enfortumab vedotin in bladder cancer models, including drug-resistant ones.
M Mithridate
	Talk Wed Oct 14 14:50 Creating customized enzymes through molecular fusion of single domain antibodies with catalytic enzyme sequences. How fusing a single-domain antibody to a clot-regulating enzyme helps it evade the autoantibodies behind acquired thrombotic thrombocytopenic purpura.
P PanTarg
	Talk Wed Oct 14 15:10 Unveiling the PanCancer potential of dual-mechanistic uPAR-targeting ADCs across cancers Armed antibodies
Abzena
abzena.com CDMO & CROSilver sponsor Integrated CDMO and CRO for bioconjugates, including ADCs, AOCs and RDCs, and complex biologics, from discovery through commercialization.	Booth Exhibiting at Booth 409
BP BSP Pharmaceuticals Latina, Italy
CDMO & CRO Italian CDMO specializing in highly potent and cytotoxic drugs, including antibody-drug conjugate manufacturing and fill-finish.	Booth Exhibiting at Booth 266
GenLumina Leiden, Netherlands
genlumina.com Biotech Startup developing a light-activated payload platform that adds spatial control to targeted cancer therapies.	Booth Exhibiting at Booth S29
Axplora
axplora.com CDMO & CRO Contract manufacturer of complex active pharmaceutical ingredients, including highly potent ADC payloads and linkers.	Booth Exhibiting (no floor booth listed)